Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $750.00 by Analysts at Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by Cantor Fitzgerald from $785.00 to $750.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 14.63% from the stock’s previous close.

A number of other analysts have also recently commented on REGN. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Finally, Truist Financial cut their price target on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $790.48.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $654.27 on Monday. Regeneron Pharmaceuticals has a fifty-two week low of $532.60 and a fifty-two week high of $821.11. The firm’s 50 day moving average price is $652.48 and its 200 day moving average price is $725.31. The stock has a market cap of $69.17 billion, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $8.22 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals will post 37.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $226,000. Arrowstreet Capital Limited Partnership acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $3,183,000. Gabelli Funds LLC raised its holdings in Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.